Breaking News

Emergent Names Management for Spin-off

January 21, 2016

Bioscience company Aptevo Therapeutics to be operational mid-2016

Emergent BioSolutions has announced the executive management team of Aptevo Therapeutics, Emergent’s planned biosciences business spin-off company. Members of the Aptevo executive management team will be appointed to their positions effective upon completion of the tax-free spin-off of Aptevo, expected to occur in mid-2016.

“We are pleased to have such an experienced and talented group of individuals to lead Aptevo Therapeutics,” said Daniel Abdun-Nabi, president and chief executive officer, Emergent BioSolutions. “These individuals possess the expertise, commitment and passion to build on the successes of Emergent’s biosciences business for it to grow as a stand-alone publicly-traded company.”

As previously announced, Marvin White will serve as Aptevo’s chief executive officer. He will be joined on the executive management team by the following individuals: Jeff Lamothe, senior vice president and chief financial officer; Scott Stromatt, chief medical officer and senior vice president, clinical development and medical affairs; Jane Gross, vice president, research and non-clinical development; Mike Adelman, vice president, commercial operations; and Shawnte Mitchell, vice president and general counsel.

“The selected management team and I share the same enthusiasm about what Aptevo can accomplish within the immuno-oncology field,” said Mr. White. “We look forward to applying our innovative Adaptir technology to provide novel oncology and hematology therapeutics that could meaningfully improve patients’ lives.”
blog comments powered by Disqus